cediranib + rifampicin

A combination of **cediranib**, a potent oral small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases (VEGFR-1, VEGFR-2, VEGFR-3) and stem cell factor receptor (c-kit), and **rifampicin**, a broad-spectrum antibiotic of the rifamycin class that is mainly used to treat tuberculosis and other bacterial infections. **Cediranib** acts as an anti-angiogenic agent, inhibiting tumor blood vessel formation and is developed primarily for oncology indications, particularly recurrent ovarian and other advanced cancers[1][5][7][8]. **Rifampicin** is a strong inducer of cytochrome P450 enzymes, particularly CYP3A4, which can dramatically affect the metabolism of other drugs such as cediranib. This combination is not a commercial product, but may be studied in drug-drug interaction research due to the known interaction: rifampicin induces hepatic metabolism, potentially lowering cediranib plasma concentrations and efficacy.

Other names

cediranib maleaterifampin